Stephenson testing drug for prostate cancer patientsPublished: Monday, September 23, 2019 By: Journal Record Staff Source: The Journal Record
If the clinical trial proves the drug to be successful in low-risk patients, it will also benefit patients’ mental outlook, Stratton said. Most patients appreciate active surveillance because they can avoid treatment, but it can also lead to an unsettling feeling of not doing anything to keep the cancer in check, he said.
“Patients love the idea of active surveillance, but there’s also a natural feeling of wanting to do something to address the cancer,” he said. “We think this drug is something that will activate their immune system against the cancer, but their quality of life will stay the same.”
Urologic oncologist Michael Cookson, chairman of the Department of Urology at the University of Oklahoma College of Medicine, said the Provenge trial is unique in offering men without symptoms of their prostate cancer the opportunity to see if their immune system can further reduce the risk of the cancer progressing.
“We’ve made major contributions to national clinical trials with our prostate cancer patients, who are brave and willing to allow us to try to move the science forward,” Cookson said.
Read the story on JournalRecord.com.